Clinical Trials · NCT02964247
LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 303
- Start date
- Mar 2017
- Locations
- 82 sites, 7 countries
- Primary endpoint
- Change in HbA1c